Literature DB >> 19478213

Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis.

Maarten G Lansberg1, Erich Bluhmki, Vincent N Thijs.   

Abstract

BACKGROUND AND
PURPOSE: The Third European Cooperative Acute Stroke Study (ECASS-3) demonstrated a benefit of treatment with intravenous tissue plasminogen activator (tPA) for acute stroke in the 3- to 4.5-hour time-window. Prior studies, however, have failed to demonstrate a significant benefit of tPA for patients treated beyond 3 hours. The purpose of this study was to produce reliable and precise estimates of the treatment effect of tPA by pooling data from all relevant studies.
METHODS: A metaanalysis was undertaken to determine the efficacy of tPA in the 3- to 4.5-hour time-window. The effect of tPA on favorable outcome and mortality was assessed.
RESULTS: The metaanalysis included data from patients treated in the 3- to 4.5-hour time-window in ECASS-1 (n=234), ECASS-2 (n=265), ECASS-3 (n=821) and The Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS) (n=302). tPA treatment was associated with an increased chance of favorable outcome (odds ratio 1.31; 95% CI: 1.10 to 1.56; P=0.002) and no significant difference in mortality (odds ratio 1.04; 95% CI: 0.75 to 1.43; P=0.83) compared to placebo treated patients.
CONCLUSIONS: Treatment with tPA in the 3- to 4.5-hour time-window is beneficial. It results in an increased rate of favorable outcome without adversely affecting mortality.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19478213      PMCID: PMC2725521          DOI: 10.1161/STROKEAHA.109.552547

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  6 in total

1.  Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.

Authors:  W M Clark; S Wissman; G W Albers; J H Jhamandas; K P Madden; S Hamilton
Journal:  JAMA       Date:  1999-12-01       Impact factor: 56.272

2.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

3.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.

Authors:  Werner Hacke; Markku Kaste; Erich Bluhmki; Miroslav Brozman; Antoni Dávalos; Donata Guidetti; Vincent Larrue; Kennedy R Lees; Zakaria Medeghri; Thomas Machnig; Dietmar Schneider; Rüdiger von Kummer; Nils Wahlgren; Danilo Toni
Journal:  N Engl J Med       Date:  2008-09-25       Impact factor: 91.245

4.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.

Authors:  W Hacke; M Kaste; C Fieschi; R von Kummer; A Davalos; D Meier; V Larrue; E Bluhmki; S Davis; G Donnan; D Schneider; E Diez-Tejedor; P Trouillas
Journal:  Lancet       Date:  1998-10-17       Impact factor: 79.321

5.  Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials.

Authors:  Werner Hacke; Geoffrey Donnan; Cesare Fieschi; Markku Kaste; Rüdiger von Kummer; Joseph P Broderick; Thomas Brott; Michael Frankel; James C Grotta; E Clarke Haley; Thomas Kwiatkowski; Steven R Levine; Chris Lewandowski; Mei Lu; Patrick Lyden; John R Marler; Suresh Patel; Barbara C Tilley; Gregory Albers; Erich Bluhmki; Manfred Wilhelm; Scott Hamilton
Journal:  Lancet       Date:  2004-03-06       Impact factor: 79.321

6.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)

Authors:  W Hacke; M Kaste; C Fieschi; D Toni; E Lesaffre; R von Kummer; G Boysen; E Bluhmki; G Höxter; M H Mahagne
Journal:  JAMA       Date:  1995-10-04       Impact factor: 56.272

  6 in total
  83 in total

Review 1.  The epidemiology, evaluation and treatment of stroke in adults with sickle cell disease.

Authors:  John J Strouse; Sophie Lanzkron; Victor Urrutia
Journal:  Expert Rev Hematol       Date:  2011-12       Impact factor: 2.929

2.  Construction, expression and refolding of a bifunctional fusion protein consisting of C-terminal 12-residue of hirudin-PA and reteplase.

Authors:  Ling Gao; Chun Zhang; Lingling Li; Lan Liang; Xuan Deng; Wutong Wu; Zhiguo Su; Rong Yu
Journal:  Protein J       Date:  2012-04       Impact factor: 2.371

Review 3.  NAD+ depletion or PAR polymer formation: which plays the role of executioner in ischaemic cell death?

Authors:  C Siegel; L D McCullough
Journal:  Acta Physiol (Oxf)       Date:  2011-01-19       Impact factor: 6.311

4.  Predictors of in-hospital death and symptomatic intracranial hemorrhage in patients with acute ischemic stroke treated with thrombolytic therapy: Paul Coverdell Acute Stroke Registry 2008-2012.

Authors:  Xin Tong; Mary G George; Quanhe Yang; Cathleen Gillespie
Journal:  Int J Stroke       Date:  2013-09-12       Impact factor: 5.266

Review 5.  Taking a light approach to treating acute ischemic stroke patients: transcranial near-infrared laser therapy translational science.

Authors:  Paul A Lapchak
Journal:  Ann Med       Date:  2010-11-01       Impact factor: 4.709

6.  Fast neuroprotection (fast-NPRX) for acute ischemic stroke victims: the time for treatment is now.

Authors:  Paul A Lapchak
Journal:  Transl Stroke Res       Date:  2013-11-07       Impact factor: 6.829

7.  Integrated Histotripsy and Bubble Coalescence Transducer for Thrombolysis.

Authors:  Aiwei Shi; Jonathan Lundt; Zilin Deng; Jonathan Macoskey; Hitinder Gurm; Gabe Owens; Xi Zhang; Timothy L Hall; Zhen Xu
Journal:  Ultrasound Med Biol       Date:  2018-09-30       Impact factor: 2.998

8.  Augmenting collateral blood flow during ischemic stroke via transient aortic occlusion.

Authors:  Ian R Winship; Glenn A Armitage; Gomathi Ramakrishnan; Bin Dong; Kathryn G Todd; Ashfaq Shuaib
Journal:  J Cereb Blood Flow Metab       Date:  2013-09-18       Impact factor: 6.200

9.  Safety and efficacy evaluation of carnosine, an endogenous neuroprotective agent for ischemic stroke.

Authors:  Ok-Nam Bae; Kelsey Serfozo; Seung-Hoon Baek; Ki Yong Lee; Anne Dorrance; Wilson Rumbeiha; Scott D Fitzgerald; Muhammad U Farooq; Bharath Naravelta; Archit Bhatt; Arshad Majid
Journal:  Stroke       Date:  2012-12-18       Impact factor: 7.914

10.  A Mouse Brain-based Multi-omics Integrative Approach Reveals Potential Blood Biomarkers for Ischemic Stroke.

Authors:  Alba Simats; Laura Ramiro; Teresa García-Berrocoso; Ferran Briansó; Ricardo Gonzalo; Luna Martín; Anna Sabé; Natalia Gill; Anna Penalba; Nuria Colomé; Alex Sánchez; Francesc Canals; Alejandro Bustamante; Anna Rosell; Joan Montaner
Journal:  Mol Cell Proteomics       Date:  2020-08-31       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.